Log In
Print
BCIQ
Print
Print this Print this
 

SYL1001

  Manage Alerts
Collapse Summary General Information
Company Sylentis S.A.
DescriptionShort interfering RNAs (siRNAs) against transient receptor potential vanilloid I (TRPV1; VR1)
Molecular Target Transient receptor potential vanilloid 1 (TRPV1) (VR1)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase II
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat discomfort associated with dry eye syndrome
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today